II Ibero-Latin American Forum of AATD On December 14, 2020, the II Ibero-Latin American Forum of DAAT (IBLA-AATD) took place. In this II Ibero-Latin American Forum on Alpha-1 Antitrypsin Deficiency, the current situation of diagnosis and treatment of AATD in our environment is addressed. However, given the pandemic situation, it has been held in virtual
II Ibero-Latin American Forum of AATD Read More »
People who suffer from it have very low amounts of the protein Alpha 1 Antitrypsin. This protein is produced by our body, mainly in the liver, from there it passes into the blood and is distributed throughout the body. Its main function is to protect the lungs and other organs from some substances that can
Alpha-1 antitrypsin deficiency is a rare inherited disease The AAT gene consists of two alleles, which are passed from parent to child by simple, autosomal, and codominant Mendelian inheritance. Each child receives an allele from each of its parents. Normal alleles, present in 85-90% of individuals, are called M, and therefore a normal individual receives
Alpha 1 deficiency as a hereditary disease Read More »
Research on Genetic Diseases Today, November 10, 2020, we celebrate Science Day. We want to make special mention of the evolution in genetic treatments. Evolution in science Genetic therapy uses genetic material to treat diseases of this group, which, as we already know, Alpha 1 Antitrypsin Deficiency is part of it. This therapy tries to
Science Day: Genetic Treatments Read More »
The human trial begins, of the treatment that acts on the liver, due to the protein Alpha-1 Antitrypsin. Almost all cases of AATD are caused by a single mutation in the A1AT gene, known as the ‘Z mutation’. Z Factor, the Cambridge-based drug development company, has administered the first human volunteer ZF874, their novel treatment
The first clinical trial begins to solve the folding of the liver caused by protein Z Read More »
Takeda and Arrowhead collaborate to develop and commercialize ARO-AAT Takeda and Arrowhead Team Up to Unveil Active Liver, Targeted to the Alpha-1 Community. “This agreement also supports the strategy of selectively partnering to continue investing in the targeted RNAi molecule (TRiMTM) platform”. They also come together to manage the growing portfolio of RNAi therapeutics targeting
The union of two pharmaceutical giants: Takeda and Arrowhead Read More »
The second phase of treatment is already underway Arrowhead ARO-AAT Phase 2 interim results in patients with alpha-1 liver disease demonstrate improvements in key parameters after six months of treatment. PASADENA, California Arrowhead Pharmaceuticals Inc. announced this September 2020 interim positive 24-week liver biopsy results in four subjects from AROAAT2002. An open-label phase 2 clinical
Research on the treatment for the cure of Alpha 1 Deficiency continues to advance Read More »
Recommendations to all health workers The Spanish Society of Preventive Medicine, Public Health and Hygiene makes 5 fundamental recommendations to prevent the transmission of the virus in the social and work environment. The role of health center staff is very important. Preventing the transmission of SARS-CoV-2 is essential. 1. Maximize distances Always keep a safe
